Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic solution, U...

FDA Drug Recall #D-0469-2023 — Class II — February 23, 2023

Recall Summary

Recall Number D-0469-2023
Classification Class II — Moderate risk
Date Initiated February 23, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Teva Pharmaceuticals USA Inc
Location Parsippany, NJ
Product Type Drugs
Quantity 715,632 bottles

Product Description

Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic solution, USP, 0.2%, Antihistamine, 2.5 mL (0.085 fl oz) bottle, Sterile, Distributed by Medtech Products Inc. Tarrytown, NY 10591, A Prestige Consumer Healthcare company, Made in Israel, UPC 678112000708; NDC 67172-504-01.

Reason for Recall

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Distribution Pattern

Nationwide in the U.S.A.

Lot / Code Information

Lot #114349, Exp. 05/2023; 117396, Exp. 09/2023; 120128, Exp. 11/2023; 114371, Exp. 06/2023; 123781, Exp. 02/2024.

Other Recalls from Teva Pharmaceuticals USA Inc

Recall # Classification Product Date
D-0913-2023 Class II Sunitinib Malate Capsules, 12.5 mg, 28-count bo... Jul 5, 2023
D-0767-2023 Class III Fentanyl Buccal Tablets CII, 200mcg, packaged i... Apr 27, 2023
D-0769-2023 Class III Fentanyl Buccal Tablets CII, 600mcg, packaged i... Apr 27, 2023
D-0770-2023 Class III Fentanyl Buccal Tablets CII, 800mcg, packaged i... Apr 27, 2023
D-0768-2023 Class III Fentanyl Buccal Tablets CII, 400mcg, packaged i... Apr 27, 2023

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.